Two weeks before admission after an exacerbation of peptic symptoms, a gastroscopy showed extensive erosive biliary gastritis, with fresh blood loss. A full blood count at that time was normal: Hb 14-0 g/dl; WBC 7.5X 10'/l; and platelets 350x 109/l. De-Nol (two tablets tid) was prescribed. He was taking no other medications.
Discussion
Two weeks before admission after an exacerbation of peptic symptoms, a gastroscopy showed extensive erosive biliary gastritis, with fresh blood loss. A full blood count at that time was normal: Hb 14-0 g/dl; WBC 7.5X 10'/l; and platelets 350x 109/l. De-Nol (two tablets tid) was prescribed. He was taking no other medications.
On admission he was apyrexial and had evidence of widespread bleeding: oral haemorrhagic vesicles; widespread petechiae; epistaxes; melaena and fresh blood per rectum; and microscopic haematuria. A full blood count revealed severe thrombocytopenia: the platelet count was <10x 109/l. The remainder of his FBC was normal (Hb 14*3 g/dl, WBC 9-0x 109/1).
Morphology of the blood film, full coagulation screen, and biochemical profile (electrolytes, LFTs) were also normal. Acute and convalescent viral titres It is a common misconception that De-Nol is not absorbed from the gastrointestinal tract. Bismuth has been shown to be absorbed after De-Nol therapy in minute quantities, reaching a mean blood concentrations of approximately 7 rig/l after four weeks' treatment. Although this is well below the proposed toxic threshold of 100 [tg/l, it is possible that the widespread erosive lesions in this patient facilitated increased absorption of bismuth. Alternatively, absorbed bismuth even in a low concentration may be enough to induce an idiosyncratic drug reaction.
Acute thrombocytopenia has not previously been reported as an adverse reaction after De-Nol treatment.' The temporal relationship of drug administration, the severity of symptoms, and the rapid recovery of the bone marrow after withdrawal of the De-Nol in this patient suggests an idiosyncratic drug reaction.
This reaction has been reported to the manufacturers and to the CSSM. 1016
